semaglutide not being sold anymore semaglutide shortage - Is compoundedsemaglutidegoing away semaglutide shortage has officially ended in the US The Semaglutide Shortage is Officially Over: What This Means for Patients and Pharmacies

Alternative to compoundedsemaglutide The extensive semaglutide shortage that has impacted patients and healthcare providers for a significant period has officially ended. On February 21, 2025, the U.S.2025年2月21日—Wegovy and Ozempic, both known chemically as semaglutide, were in shortage in the U.S. for much of last year. Americans who cannot afford Wegovy ... Food and Drug Administration (FDA) declared that the shortage of semaglutide injection products has been resolved.These “compounded” versions are going away soon. If that sounds confusing or scary, don't worry. This blog will help you understand what's happening and why. This pivotal announcement signifies a major shift in the availability of popular GLP-1 medications, including Ozempic and Wegovy, both of which are chemically known as semaglutide.

For a considerable time, the scarcity of these semaglutide medications led to widespread concern and a surge in the use of compounded versions. However, the FDA's declaration that the semaglutide shortage has been resolved means these semaglutide injection products from Novo Nordisk are now being continuously shipped and are meeting or exceeding expected U.S. demand.Are Compounded GLP-1s Going Away? Not Entirely This means semaglutide is no longer in short supply in its FDA-approved forms.FDA has determined the shortage ofsemaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved. The previous assertion that there was no shortage is now a reality2026年2月19日—FDA removed semaglutide from the drug shortage list in February 2025. When the U.S. Food and Drug Administration declared that Ozempic® and ....

The End of Compounded Semaglutide Sales

One of the most significant implications of the resolved semaglutide shortage is the phasing out of compounded versions of the drugSemaglutide officially declared no longer on shortage. These less expensive, off-brand alternatives were permitted by the FDA during the shortage period as an interim solution. However, with the official resolution, compounding pharmacies can no longer make and sell semaglutide injections after a grace period2026年2月19日—FDA removed semaglutide from the drug shortage list in February 2025. When the U.S. Food and Drug Administration declared that Ozempic® and .... Federal deadlines have been set, and by specific dates, such as May 22, 2025, and Thursday (referring to the deadline following the FDA's announcement), these compounded versions must be out of the market.

This directive means that many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs.Did the FDA ban compounded semaglutide? The FDA has taken action, leading to cease-and-desist letters from manufacturers like Novo Nordisk and Eli Lilly. Consequently, the sale of compounded versions of some weight loss medications like Ozempic and Zepbound has been halted or is in the process of being restricted. The era of compounded semaglutide being readily available is drawing to a close, with the FDA’s removal of semaglutide from the drug shortage list in February 2025 being the catalyst2025年2月24日—With Novo Nordisk's blockbuster drugs Wegovy and Ozempic back in stock, copycat versions ofsemaglutide are no longer allowed– for now..

What This Means for Patients and the Future of GLP-1 Medications

For patients who rely on semaglutide for managing their diabetes or for weight loss, the end of the shortage means greater access to the authentic, FDA-approved medications.Makers of compounded Wegovy, Ozempic threatened by FDA ... The supply of the only real, FDA-approved semaglutide medicines is resolved, ensuring that patients can obtain their prescribed treatments without the uncertainty of shortages. This also implies that the semaglutide shortage has officially ended in the U.S.2025年5月23日—The FDA has banned compounded versions of GLP-1 drugs likesemaglutideor tirzepatide due to safety concerns, and supplies of these copycats ..., leading to significant changes in the GLP-1 drug industry2025年2月28日—The FDA's recent decision to removesemaglutidefrom the drug shortage list marks a significant shift for compounding pharmacies..

The FDA's clarification of its policies for compounders, following the end of the semaglutide shortage over, marks a definitive step. While some may inquire about why compounded tirzepatide actions are different or if compounded semaglutide is still available, the general consensus is that the market for these copycat versions is significantly diminishing. Pharmacists do not believe that compounded GLP-1s will disappear completely, but their availability and legality are now under much stricter scrutiny, especially in the absence of an official shortage2025年5月27日—After announcing the ends of the shortages, FDA gave the impacted companies a facility-dependent grace period of 60 to 90 days to stopselling....

The surge in prescriptions for semaglutide for weight loss was a contributing factor to the global supply issues. Now that the supply chain is stabilizing, the focus shifts back to the approved indications and responsible prescription practices. While some companies may explore alternatives to compounded semaglutide, the primary path forward involves accessing the FDA-approved semaglutide products.

It's important to note that the FDA has also warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, or retatrutide that are falsely labeled. These actions are a critical part of ensuring patient safety and drug integrity2025年2月21日—All semaglutide doses are now being “continuously shipped”to wholesalers and “meeting or exceeding expected U.S. demand,” Novo Nordisk said ....

In conclusion, the semaglutide shortage has officially ended in the US, bringing relief to many.FDA Ban on Compounded GLP-1 Drugs: What to Know While the landscape of GLP-1 medications is evolving, the resolution of the shortage ensures greater accessibility to semaglutide for those who need it, while also bringing regulated clarity to the market concerning compounded alternativesFDA Halts Sale of Off-Brand Ozempic and Other GLP-1 Drugs. The era of the semaglutide shortage is over, and the industry is now navigating a new phase of availability and regulation.